Webinar-Recorded

Critical Role of Forced Degradation in Method Development of mAbs

Forced degradation studies are crucial for developing recombinant monoclonal antibody therapeutics, aiding in everything from early manufacturability checks to comparability assessments before and after marketing approval. For this study, an IgG1 antibody was subjected to numerous forced degradation pathways and analyzed by SV-AUC (Sedimentation Velocity-Analytical Ultracentrifugation), SEC-MALS (Size-exclusion chromatography multi-angle light scattering), and DLS (Dynamic Light Scattering) to determine sedimentation coefficient, percent distribution, molecular weight, polydispersity, and overall particle size analysis. The individual and orthogonal results from the methods will be presented and discussed in regard to the conditions the molecule was subjected to.

Learn more about:

Understand the importance of forced degradation studies in the development and quality assessment of biotherapeutics.

Learn how advanced techniques help to understand and evaluate stability and critical quality attributes.

Explore how data from forced degradation studies inform method development and manufacturability decisions.

Business Email Address*

First Name*

Last Name*

Company*

Title*

Business Phone

Country

State or Province

Buying Horizon*

Asset ID

Asset Type

Asset URL

Download Center - Date Stamp

Download Center - Visit Count

ZZ - Last SFDC Campaign ID

Unique ID

Browser

auxCountry

auxState

Why Catalent?

Catalyst + Talent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™